Antiplatelet or anticoagulative strategies after surgical/interventional valve treatment
At the end of August 2017 the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) published new joint guidelines for the treatment of valvular heart disease. These guidelines incorporate the scientific progress since the last version of the guideline...
Gespeichert in:
| Veröffentlicht in: | Herz 2018-02, Vol.43 (1), p.26-33 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | ger |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 33 |
|---|---|
| container_issue | 1 |
| container_start_page | 26 |
| container_title | Herz |
| container_volume | 43 |
| creator | Jobs, A Stiermaier, T Klotz, S Eitel, I |
| description | At the end of August 2017 the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) published new joint guidelines for the treatment of valvular heart disease. These guidelines incorporate the scientific progress since the last version of the guidelines published in 2012. This article reviews current guideline recommendations for antiplatelet and anticoagulative therapy after surgical/interventional treatment of the aortic and mitral valves and discusses the underlying scientific evidence. |
| doi_str_mv | 10.1007/s00059-017-4646-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1966244673</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1966244673</sourcerecordid><originalsourceid>FETCH-LOGICAL-p141t-c83467c0a396debbd52b0bf5ce54b6113c3c1401b4450990573f7c9a2b91bb623</originalsourceid><addsrcrecordid>eNo1kEtLAzEUhYMgtlZ_gBuZpZux9-ZplqX4goIbBXdDkmbKSOZhkin47w1YV4dz7sc9cAi5QbhHALVOACB0DahqLrms6RlZokRRS6npglym9AWAQlO4IAuqkSutcEk-N0PupmCyDz5XY6xM8W40h7lk3dFXKcdyPHQ-VabNPlZpjofOmbDuhmKPvvDjYEJ1NKHgOXqT-xJekfPWhOSvT7oiH0-P79uXevf2_Lrd7OoJOebaPTAulQPDtNx7a_eCWrCtcF5wKxGZYw45oOVcgNYgFGuV04ZajdZKylbk7u_vFMfv2afc9F1yPgQz-HFODWopKS8drKC3J3S2vd83U-x6E3-a_zXYL8JIYZo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1966244673</pqid></control><display><type>article</type><title>Antiplatelet or anticoagulative strategies after surgical/interventional valve treatment</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Jobs, A ; Stiermaier, T ; Klotz, S ; Eitel, I</creator><creatorcontrib>Jobs, A ; Stiermaier, T ; Klotz, S ; Eitel, I</creatorcontrib><description>At the end of August 2017 the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) published new joint guidelines for the treatment of valvular heart disease. These guidelines incorporate the scientific progress since the last version of the guidelines published in 2012. This article reviews current guideline recommendations for antiplatelet and anticoagulative therapy after surgical/interventional treatment of the aortic and mitral valves and discusses the underlying scientific evidence.</description><identifier>EISSN: 1615-6692</identifier><identifier>DOI: 10.1007/s00059-017-4646-2</identifier><identifier>PMID: 29147971</identifier><language>ger</language><publisher>Germany</publisher><subject>Administration, Oral ; Anticoagulants - adverse effects ; Anticoagulants - therapeutic use ; Aortic Valve - surgery ; Dose-Response Relationship, Drug ; Follow-Up Studies ; Guidelines as Topic ; Heart Valve Diseases - surgery ; Heart Valve Prosthesis Implantation ; Hemorrhage - chemically induced ; Humans ; Mitral Valve - surgery ; Platelet Aggregation Inhibitors - adverse effects ; Platelet Aggregation Inhibitors - therapeutic use ; Randomized Controlled Trials as Topic ; Risk Factors ; Thromboembolism - prevention & control</subject><ispartof>Herz, 2018-02, Vol.43 (1), p.26-33</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29147971$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jobs, A</creatorcontrib><creatorcontrib>Stiermaier, T</creatorcontrib><creatorcontrib>Klotz, S</creatorcontrib><creatorcontrib>Eitel, I</creatorcontrib><title>Antiplatelet or anticoagulative strategies after surgical/interventional valve treatment</title><title>Herz</title><addtitle>Herz</addtitle><description>At the end of August 2017 the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) published new joint guidelines for the treatment of valvular heart disease. These guidelines incorporate the scientific progress since the last version of the guidelines published in 2012. This article reviews current guideline recommendations for antiplatelet and anticoagulative therapy after surgical/interventional treatment of the aortic and mitral valves and discusses the underlying scientific evidence.</description><subject>Administration, Oral</subject><subject>Anticoagulants - adverse effects</subject><subject>Anticoagulants - therapeutic use</subject><subject>Aortic Valve - surgery</subject><subject>Dose-Response Relationship, Drug</subject><subject>Follow-Up Studies</subject><subject>Guidelines as Topic</subject><subject>Heart Valve Diseases - surgery</subject><subject>Heart Valve Prosthesis Implantation</subject><subject>Hemorrhage - chemically induced</subject><subject>Humans</subject><subject>Mitral Valve - surgery</subject><subject>Platelet Aggregation Inhibitors - adverse effects</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Risk Factors</subject><subject>Thromboembolism - prevention & control</subject><issn>1615-6692</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kEtLAzEUhYMgtlZ_gBuZpZux9-ZplqX4goIbBXdDkmbKSOZhkin47w1YV4dz7sc9cAi5QbhHALVOACB0DahqLrms6RlZokRRS6npglym9AWAQlO4IAuqkSutcEk-N0PupmCyDz5XY6xM8W40h7lk3dFXKcdyPHQ-VabNPlZpjofOmbDuhmKPvvDjYEJ1NKHgOXqT-xJekfPWhOSvT7oiH0-P79uXevf2_Lrd7OoJOebaPTAulQPDtNx7a_eCWrCtcF5wKxGZYw45oOVcgNYgFGuV04ZajdZKylbk7u_vFMfv2afc9F1yPgQz-HFODWopKS8drKC3J3S2vd83U-x6E3-a_zXYL8JIYZo</recordid><startdate>201802</startdate><enddate>201802</enddate><creator>Jobs, A</creator><creator>Stiermaier, T</creator><creator>Klotz, S</creator><creator>Eitel, I</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201802</creationdate><title>Antiplatelet or anticoagulative strategies after surgical/interventional valve treatment</title><author>Jobs, A ; Stiermaier, T ; Klotz, S ; Eitel, I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p141t-c83467c0a396debbd52b0bf5ce54b6113c3c1401b4450990573f7c9a2b91bb623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>ger</language><creationdate>2018</creationdate><topic>Administration, Oral</topic><topic>Anticoagulants - adverse effects</topic><topic>Anticoagulants - therapeutic use</topic><topic>Aortic Valve - surgery</topic><topic>Dose-Response Relationship, Drug</topic><topic>Follow-Up Studies</topic><topic>Guidelines as Topic</topic><topic>Heart Valve Diseases - surgery</topic><topic>Heart Valve Prosthesis Implantation</topic><topic>Hemorrhage - chemically induced</topic><topic>Humans</topic><topic>Mitral Valve - surgery</topic><topic>Platelet Aggregation Inhibitors - adverse effects</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Risk Factors</topic><topic>Thromboembolism - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jobs, A</creatorcontrib><creatorcontrib>Stiermaier, T</creatorcontrib><creatorcontrib>Klotz, S</creatorcontrib><creatorcontrib>Eitel, I</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Herz</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jobs, A</au><au>Stiermaier, T</au><au>Klotz, S</au><au>Eitel, I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiplatelet or anticoagulative strategies after surgical/interventional valve treatment</atitle><jtitle>Herz</jtitle><addtitle>Herz</addtitle><date>2018-02</date><risdate>2018</risdate><volume>43</volume><issue>1</issue><spage>26</spage><epage>33</epage><pages>26-33</pages><eissn>1615-6692</eissn><abstract>At the end of August 2017 the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) published new joint guidelines for the treatment of valvular heart disease. These guidelines incorporate the scientific progress since the last version of the guidelines published in 2012. This article reviews current guideline recommendations for antiplatelet and anticoagulative therapy after surgical/interventional treatment of the aortic and mitral valves and discusses the underlying scientific evidence.</abstract><cop>Germany</cop><pmid>29147971</pmid><doi>10.1007/s00059-017-4646-2</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1615-6692 |
| ispartof | Herz, 2018-02, Vol.43 (1), p.26-33 |
| issn | 1615-6692 |
| language | ger |
| recordid | cdi_proquest_miscellaneous_1966244673 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Administration, Oral Anticoagulants - adverse effects Anticoagulants - therapeutic use Aortic Valve - surgery Dose-Response Relationship, Drug Follow-Up Studies Guidelines as Topic Heart Valve Diseases - surgery Heart Valve Prosthesis Implantation Hemorrhage - chemically induced Humans Mitral Valve - surgery Platelet Aggregation Inhibitors - adverse effects Platelet Aggregation Inhibitors - therapeutic use Randomized Controlled Trials as Topic Risk Factors Thromboembolism - prevention & control |
| title | Antiplatelet or anticoagulative strategies after surgical/interventional valve treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T19%3A53%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiplatelet%20or%20anticoagulative%20strategies%20after%20surgical/interventional%20valve%20treatment&rft.jtitle=Herz&rft.au=Jobs,%20A&rft.date=2018-02&rft.volume=43&rft.issue=1&rft.spage=26&rft.epage=33&rft.pages=26-33&rft.eissn=1615-6692&rft_id=info:doi/10.1007/s00059-017-4646-2&rft_dat=%3Cproquest_pubme%3E1966244673%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1966244673&rft_id=info:pmid/29147971&rfr_iscdi=true |